LncRNA IGF2-AS表达上调促进结直肠癌的进展

doi:10.16352/j.issn.1001-6325.2025.03.0323

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (3): 323-330.doi: 10.16352/j.issn.1001-6325.2025.03.0323

LncRNA IGF2-AS表达上调促进结直肠癌的进展

崔丽娇¹, 吴秀¹, 顾志伟¹, 周宇^1,2*, 喻才元^1*

1.广东医科大学附属医院消化内科,广东湛江 524001;
2.广东医科大学,广东湛江 524023

收稿日期:2024-08-27 修回日期:2024-10-30 发布日期:2025-02-25
通讯作者: ^*gdmcycy2013@126.com;ahdg2022@gdmu.edu.cn
基金资助:
广东医科大学科研基金(GDMUM2020010,GDMUM2020013);广东省医学科学技术研究基金(B2023050);湛江市科技攻关计划(2020B01353);广东省自然科学基金(2023A1515010530)

Up-regulation of lncRNA IGF2-ASexpression promotes progression of colorectal cancer

CUI Lijiao¹, WU Xiu¹, GU Zhiwei¹, ZHOU Yu^1,2*, YU Caiyuan^1*

1. Department of Gastroenterology, the Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001;
2. Guangdong Medical University, Zhanjiang 524023, China

Received:2024-08-27 Revised:2024-10-30 Published:2025-02-25

摘要/Abstract

摘要： 目的了解lncRNA IGF2-AS在结直肠癌中的表达及临床意义;验证胰岛素样生长因子2反义链(IGF2-AS)在细胞中的生物学功能;筛选受IGF2-AS调控的蛋白分子。方法利用生物信息学预测IGF2-AS在结直肠癌中的表达和临床意义;运用RT-qPCR检测IGF2-AS mRNA的表达;运用小干扰RNA敲低IGF2-AS;运用CCK8法、Transwell小室法和流式细胞测量术分别检测细胞的增殖、迁移和凋亡;利用Label-free定量蛋白质组学筛选受IGF2-AS调控的相关因子;运用GenCards、OMIM、TTD等数据库结合蛋白质组学结果筛选出结直肠癌中受IGF2-AS调控的核心靶点。结果生物信息分析表明,IGF2-AS在结直肠癌中显著上调(P＜0.001),且其表达可能与肿瘤TNM分期(P＜0.01)及有无淋巴结转移(P＜0.001)相关;RT-qPCR结果表明,与对照组相比IGF2-AS mRNA在结直肠癌组织和大多数结肠癌细胞中的表达显著上调(P＜0.01);临床资料表明,IGF2-AS的表达可能与淋巴结转移(P＜0.05)相关;生物学功能实验结果表明,IGF2-AS siRNA转染组结直肠癌细胞增殖率及迁移率均显著减低 (P＜0.000 1),凋亡率显著增加(P＜0.05);KRAS、TCF7L2、CASP3等13个蛋白可能是受IGF2-AS调控的核心靶点。结论 IGF2-AS在结直肠癌中表达显著上调,可能发挥促癌作用。

关键词: 结直肠癌, 长链非编码RNA, 胰岛素样生长因子2反义链(IGF2-AS)

Abstract: Objective To investigate the expression and clinical significance of lncRNA insulin growth factor 2 antisense IGF2-AS in colorectal cancer; To verify the biological function of IGF2-AS in cells and to screen protein molecules regulated by IGF2-AS. Methods Using bioinformatics to predict the expression and clinical significance of IGF2-AS in colorectal cancer; Using RT-qPCR to detect the expression of IGF2-AS mRNA; Using small interfering RNA to knockdown IGF2-AS; Using CCK8, Transwell assay and flow cytometry to detect proliferation, migration, and apoptosis, respectively; Using label free quantitative proteomics to screen for factors regulated by IGF2-AS; Using databases such as GenCards, OMIM, TTD, and proteomics Results screening for core targets regulated by IGF2-AS in colorectal cancer. Results Bioinformatics analysis showed that IGF2-AS was significantly upregulated in colorectal cancer(P＜0.001), its expression might be related to TNM stage (P＜0.01) and the presence of lymph node metastasis(P＜0.001); RT-qPCR Results showed that as compared to the control group, the expressionlevel of IGF2-AS mRNA was significantly up-regulated in colorectal cancer tissues (P＜0.01) and most colon cancer cells(P＜0.000 1); Clinical pathological data indicated that the expression of IGF2-AS was potentially associated with the lymph node metastasis (P＜0.05); The proliferation rate and migration rate of colorectal cancer cells transfected with IGF2-AS siRNA were significantly reduced (P＜0.000 1), and the apoptosis rate was significantly increased (P＜0.05); There were 13 proteins including KRAS, TCF7L2 and CASP3, that were potentially core targets regulated by IGF2-AS.Conclusions IGF2-AS is significantly up-regulated in colorectal cancer and may play a cancer promoting role in colorectal cancer development.

Key words: colorectal cancer, long non-coding RNA, insulin like growth factor 2 antisense(IGF2-AS)

中图分类号:

R574.6

崔丽娇, 吴秀, 顾志伟, 周宇, 喻才元. LncRNA IGF2-AS表达上调促进结直肠癌的进展[J]. 基础医学与临床, 2025, 45(3): 323-330.

CUI Lijiao, WU Xiu, GU Zhiwei, ZHOU Yu, YU Caiyuan. Up-regulation of lncRNA IGF2-ASexpression promotes progression of colorectal cancer[J]. Basic & Clinical Medicine, 2025, 45(3): 323-330.

参考文献

[1] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394: 1467-1480.
[2] Lin H, Guo Q, Lu S, et al. LncRNA SUMO1P3 promotes proliferation and inhibits apoptosis in colorectal cancer by epigenetically silencing CPEB3[J]. Biochem Biophys Res Commun, 2019, 511: 239-245.
[3] Buccafusca G, Proserpio I, Tralongo AC, et al. Early colorectal cancer: diagnosis, treatment and survivorship care[J]. Crit Rev Oncol Hematol, 2019, 136: 20-30.
[4] Fenocchio E. Rethinking colorectal cancer prognosis: beyond microsatellite status[J]. Lancet Gastroenterol Hepatol, 2024, 9: 585-586.
[5] Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009, 136: 629-641.
[6] Morlando M, Ballarino M, Fatica A, et al. The Role of long noncoding RNAs in the epigenetic control of gene expression[J]. Chem Med Chem, 2014, 9: 505-510.
[7] Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8:1015. doi: 10.3390/cells8091015.
[8] Huang J, Chen YX, Zhang B. IGF2-AS affects the prognosis and metastasis of gastric adenocarcinoma via acting as a ceRNA of miR-503 to regulate SHOX2[J]. Gastric Cancer[J]. 2020, 23: 23-38.
[9] Xiang Y, Zong QB, Liu H, et al. LncRNA IGF2-AS regulates miR-500a-3p/PPP4R1/p-VEGFR2 signalling pathway to promote thyroid carcinoma progression and tubulogenesis[J]. Clin Transl Med, 2023, 13: e1240. doi: 10.1002/ctm2.1240.
[10] Yan B, Ren Z, Sun J, et al. IGF2-AS knockdown inhibits glycolysis and accelerates apoptosis of gastric cancer cells through targeting miR-195/CREB1 axis[J]. Biomed Pharmacother, 2020, 130: 110600. doi: 10.1016/j.biopha.2020.110600.
[11] Liu B, Liu Y, Zhou M, et al. Comprehensive ceRNA network analysis and experimental studies identify an IGF2-AS/miR-150/IGF2 regulatory axis in colorectal cancer[J]. Pathol Res Pract, 2020, 216: 153104. doi: 10.1016/j.prp.2020.153104.
[12] Bao H, Guo CG, Qiu PC, et al. Long non coding RNA IGF2-AS controls hepatocellular carcinoma progression through the ERKMAPK signaling pathway[J]. Oncol Lett, 2017, 14: 2831-2837.
[13] Zhang Z, Qian W, Wang S, et al. Analysis of lncRNA-associated ceRNA network reveals potential lncRNA biomarkers in human colon adeno carcinoma[J]. Cell Physiol Biochem, 2018, 49: 1778-1791.
[14] Zhu G, Pei L, Xia H, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer[J]. Mol Cancer, 2021, 20: 143. doi: 10.1186/s12943-021-01441-4.
[15] Duan B, Zhou X, Zhang X, et al. BRD4-binding enhancer promotes CRC progression by interacting with YY1 to activate the Wnt pathway through upregulation of TCF7L2[J]. Biochem Pharmacol, 2023, 218: 115877. doi: 10.1016/j.bcp.2023.115877.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	17

	来源	本网站

	次数	17
	比例	100%

摘要

最新录用	在线预览	正式出版

0	0	59

	来源	本网站

	次数	59
	比例	100%

LncRNA IGF2-AS表达上调促进结直肠癌的进展

Up-regulation of lncRNA IGF2-ASexpression promotes progression of colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐 0

Metrics

本文评价

[1]	张树军, 栗甜甜, 钟明亮, 张剑, 董欣敏. 维生素D在防治结直肠癌及补充应用的研究进展[J]. 基础医学与临床, 2025, 45(3): 404-408.
[2]	刘艳彩, 刘学刚, 张振亚. 下调CD151联合贝伐珠单抗抑制结直肠癌生长与微血管密度[J]. 基础医学与临床, 2025, 45(1): 20-24.
[3]	郑红, 陈晓霞, 韩李周, 陈苗, 皇甫娟. 降低lncRNA-RMRP表达抑制人肺癌细胞系A549的增殖和侵袭[J]. 基础医学与临床, 2024, 44(7): 974-978.
[4]	王乾宇, 吴斌. 内镜OTSC系统在结直肠癌术后吻合口漏(瘘)治疗中的研究进展[J]. 基础医学与临床, 2024, 44(12): 1727-1730.
[5]	杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.
[6]	张海灵, 杨玉, 周倩倩, 汪远金, 王婷. 微囊藻毒素-LR处理的中性粒细胞NETs促进结直肠癌细胞迁移[J]. 基础医学与临床, 2023, 43(6): 967-973.
[7]	张燕萍, 姚刘旭, 丁倩男, 黄则勇, 李玉红, 黄素琴. 结直肠癌PDX模型成瘤率的影响因素及临床意义[J]. 基础医学与临床, 2023, 43(4): 596-602.
[8]	王芳芳, 曹慧媛, 汪婧, 王宁, 黄国良. 上调miR-200c-5p的表达抑制人结直肠癌细胞系SW480增殖[J]. 基础医学与临床, 2023, 43(2): 241-245.
[9]	姚刘旭, 李玉红, 蒋宗明. 外泌体lncRNA在结直肠癌液体活检中的研究进展[J]. 基础医学与临床, 2023, 43(2): 317-321.
[10]	余宏, 丁利杰, 刘厚聪, 王纪东, 杜冀晖. 合成肽VAR2特异性结合循环肿瘤细胞的检测及临床应用[J]. 基础医学与临床, 2023, 43(11): 1662-1667.
[11]	苏越, 梁琳慧, 何祥火. 长链非编码RNA亚细胞定位和功能的研究进展[J]. 基础医学与临床, 2023, 43(10): 1580-1584.
[12]	邱立彬, 张新才, 赵倩. LncRNA DANCR靶向miR-3646减轻缺氧诱导的大鼠心肌细胞系H9c2的损伤[J]. 基础医学与临床, 2023, 43(1): 144-151.
[13]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.
[14]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[15]	刘磊, 李世宝, 张好良. 沉默lnc-SLC2A12-10:1抑制人胃癌细胞系AGS增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(7): 1071-1076.